<!DOCTYPE html>
<html lang="en-us"
  dir="ltr">

<head>
  <meta charset="utf-8">
<meta name="viewport" content="width=device-width">



<link rel="icon" type="image/ico" href="https://reports.muthu.co/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://reports.muthu.co/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://reports.muthu.co/favicon-32x32.png">
<link rel="icon" type="image/png" sizes="192x192" href="https://reports.muthu.co/android-chrome-192x192.png">
<link rel="apple-touch-icon" sizes="180x180" href="https://reports.muthu.co/apple-touch-icon.png">

<meta name="description" content=""/>



<title>
    
    Mankind Pharma Ltd - Jan 2025 Earnings Call Transcript Analysis | Financial Report Insights
    
</title>
<link href="/pagefind/pagefind-ui.css" rel="stylesheet">
<script src="/pagefind/pagefind-ui.js"></script>
<link rel="canonical" href="https://reports.muthu.co/posts/mankind-pharma-ltd---jan-2025-earnings-call-transcript-analysis/"/>

<meta property="og:url" content="https://reports.muthu.co/posts/mankind-pharma-ltd---jan-2025-earnings-call-transcript-analysis/">
  <meta property="og:site_name" content="Financial Report Insights">
  <meta property="og:title" content="Mankind Pharma Ltd - Jan 2025 Earnings Call Transcript Analysis">
  <meta property="og:description" content="Earnings Call Transcript Analysis Report # Financial Performance # Key Financial Metrics (Q3 FY25) # Revenue: INR 3,230 crores, up 24% YoY. Organic growth: 11.2% YoY. Domestic organic growth: 8.4% YoY. Export organic growth: 43% YoY. Adjusted EBITDA Margin: 27.7%. Reported EBITDA: INR 833 crores, up 36.4% YoY, margin of 25.8%. Gross Margins: Increased to 71% YoY from 68.3% in Q3 FY24. PAT: Decreased by 16.4% to INR 385 crores. Diluted EPS: INR 9.4 per share. Cash EPS: INR 14.2 per share. R&amp;D Expenses: INR 71 crores (2.2% of sales). Depreciation and Amortization: INR 192 crores (includes INR 84 crores amortization from BSV assets). Key Financial Metrics (9M FY25) # Revenue: Increased by 17% YoY. Adjusted EBITDA Margin: 26.9%. Reported EBITDA margin: 25.8%. Organic Growth: 12.3% YoY. Domestic organic growth: 9.3% YoY. Export organic growth: 53% YoY. Consolidated Effective Tax Rate: 21.2%. Cash Flow from Operations: INR 1,599 crores (down 2.3% YoY). Cash Flow to EBITDA Ratio: 67.4%. Capex Spends: INR 344 crores (3.7% of total revenue). Guidance &amp; Forecasts # R&amp;D Expenses: Stated guidance of 2% to 2.5% of sales. Effective Tax Rate: Guidance of 21% to 22%. Capex: Guidance of 4% to 5% of revenue. Net Debt to Adjusted EBITDA: Endeavor to achieve 2x by end of FY25. Interest Cost (Next Quarter): Expected to be in the range of INR 180-odd crores. Areas of Growth or Decline # Growth: Overall revenue (driven by both organic and BSV acquisition), export business (organic growth of 43% in Q3, 53% in 9M), OTC business (30% YoY in Q3, 15% YoY in 9M), Chronic segment share (increased by 200 bps YoY to 37.6% ex-BSV). Decline/Slowdown: PAT (due to higher finance and amortization costs), organic domestic formulation growth (around 6.5-7% in Q3, impacted by acute segment softness and corrective measures). Working Capital: Net operating working capital days increased to 52 days from 45 days in the preceding quarter. Strategic Initiatives &amp; Business Updates # BSV Acquisition &amp; Integration # Acquisition completed, BSV financials consolidated from October 23rd, 2024 (69 days in Q3). Integration is “on track.” Significant restructuring in the Rx business (TTK business of BSV), shifting to Mankind, field force optimization. Synergy benefits expected: INR 50-100 crores over 12-24 months. Corrective Measures # Delhi Pharma Divisions: Undertaken to enhance field force productivity and efficiency. Nearing completion (80-90% done). Measures include addressing inefficiencies in primary/discounted sales, doctor coverage strategy, leadership changes. OTC Division: Corrective measures completed, leading to robust growth. Product Portfolio &amp; R&amp;D # Expansion of DMF grade products: Over 215 (vs 150 in FY24), &gt;90% in chronic segment. Partnership with Innovent Biologics: In-licensing of Sintilimab (PD-1 immunotherapy for cancer treatment). Financial Strategy # Raised INR 10,000 crores (NCDs &amp; CPs) for BSV acquisition. Raised INR 3,000 crores in equity, used to repay CPs. Operational Changes # OTC business carved out into a wholly-owned subsidiary. Field force strength (Mankind): Increased from 16,043 (Mar 2024) to 16,570 (Dec 2024). Not cutting down, but replacing and optimizing. Market &amp; Competitive Landscape # Market Share &amp; Positioning # IPM market share (value): Increased by 40 bps to 4.8% (Dec ‘24) from 4.4% (Mar ‘24), “primarily driven by acquisition of BSV.” CVM Cardio Rank: Improved from 4th to 3rd in IPM. Aiming for leadership. Industry Trends # Chronic Segment Growth: Continued outperformance in key chronic therapies. Mankind’s chronic share (ex-BSV) increased to 37.6% in Q3 FY25 from 35.6% in Q3 FY24. Cancer Incidence: Rising cancer cases in India, creating demand for innovative therapies like Sintilimab. Competitive Actions/Statements # Focus on “high entry barrier portfolios” and “specialty R&amp;D tech platforms” through acquisitions like BSV. Corrective measures aimed at improving competitiveness and field force productivity against market. Market Challenges/Opportunities # Challenge: Softer acute market for Mankind due to corrective measures and some regulatory impacts. Opportunity: Expanding into specialty/super-specialty segments (BSV), growing chronic market, robust OTC market potential. Risk Factors &amp; Challenges # Corrective Actions Impact # Temporary slowdown in growth, especially in the acute segment of the domestic pharma business. BSV Integration &amp; Restructuring # Ongoing integration process for BSV. Restructuring of BSV’s Rx business leading to soft performance in that segment. Regulatory Issues # Impact on acute segment growth from regulatory tailwinds concerning emergency contraceptive pills, an FDC anti-infective, and a codeine preparation. DPCO matter affecting value growth in a gynaecology product. Financial Metrics Pressure # Higher finance costs and amortization from BSV acquisition impacting PAT. Increased working capital days. Operational Constraints # New field force members (due to replacements during corrective actions) need time to build rapport and productivity. Forward-Looking Statements # Overall Outlook # Confident in delivering sustainable long-term growth, supported by corrective actions and four growth engines. Corrective Measures Completion # Remaining 10-20% of corrective actions in Delhi pharma divisions to be completed in Q4 FY25. BSV Business # Priority is successful integration for long-term sustainable growth. Expected to grow 15%&#43; with higher export growth in the medium term. Margin improvement targeted: Starting at company average (26-28%), aiming for ~30% in 2-3 years, and “for sure in the next 5 years.” Rx business restructuring (TTK) to see improvements from Q4 onwards. Financial Targets # Net debt to adjusted EBITDA: Target of 2x by end of FY25. Interest cost next quarter: Around INR 180 crores. Product Pipeline # Planning to introduce a replacement (single molecule) for the anti-infective FDC affected by regulatory issues within a month. Future Growth # Expects growth to improve post-completion of corrective measures. Chronic PCPM expected to grow faster and eventually align with company average. Download Transcript">
  <meta property="og:locale" content="en_us">
  <meta property="og:type" content="article">
    <meta property="article:section" content="posts">
    <meta property="article:published_time" content="2025-01-30T15:12:00+00:00">
    <meta property="article:modified_time" content="2025-01-30T15:12:00+00:00">
    <meta property="article:tag" content="Mankind Pharma Ltd.">
    <meta property="article:tag" content="MANKIND">
    <meta property="article:tag" content="Branded Medicines">
    <meta property="article:tag" content="Healthcare">
    <meta property="article:tag" content="Large Cap">
    <meta property="article:tag" content="Earnings Call">













<link rel="stylesheet" href="/assets/combined.min.32c4505ff6f37c4a072861f2cbad7347d8e8e8c8f60e01107b50d77c8c29f9f6.css" media="all">




      <script async src="https://www.googletagmanager.com/gtag/js?id=G-T7PH4WNH24"></script>
      <script>
        var doNotTrack = false;
        if ( false ) {
          var dnt = (navigator.doNotTrack || window.doNotTrack || navigator.msDoNotTrack);
          var doNotTrack = (dnt == "1" || dnt == "yes");
        }
        if (!doNotTrack) {
          window.dataLayer = window.dataLayer || [];
          function gtag(){dataLayer.push(arguments);}
          gtag('js', new Date());
          gtag('config', 'G-T7PH4WNH24');
        }
      </script>




<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-3609399560636561" crossorigin="anonymous"></script>
</head>







<body class="light">
  <div class="content">
    <header>
      

<div class="header">

    
    <div id="search"></div>
</div>

    </header>
    <main class="main">
      





<div class="breadcrumbs">
    
    <a href="/">Home</a>
    <span class="breadcrumbs-separator"> > </span>
    
    <a href="/posts/">Posts</a>
    <span class="breadcrumbs-separator"> > </span>
    
    <a class="breadcrumbs-current" href="/posts/mankind-pharma-ltd---jan-2025-earnings-call-transcript-analysis/">Mankind Pharma Ltd - Jan 2025 Earnings Call Transcript Analysis</a>
</div>



<div >

  <div class="single-intro-container">

    

    <h1 class="single-title" data-pagefind-body>Mankind Pharma Ltd - Jan 2025 Earnings Call Transcript Analysis</h1>
    

    

    <p class="single-readtime">
      
      
      
      <time datetime="2025-01-30T15:12:00&#43;00:00">January 30, 2025</time>
      

      
      &nbsp; · &nbsp;
      5 min read
      
    </p>

  </div>

  

  
  

  <div class="single-tags">
    
    <span>
      <a href="https://reports.muthu.co/tags/mankind-pharma-ltd./">#Mankind Pharma Ltd.</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/mankind/">#MANKIND</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/branded-medicines/">#Branded Medicines</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/healthcare/">#Healthcare</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/large-cap/">#Large Cap</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/earnings-call/">#Earnings Call</a>
    </span>
    
    
  </div>

  
  

  

  
  <aside class="toc">
    <p><strong>Table of contents</strong></p>
    <nav id="TableOfContents">
  <ul>
    <li><a href="#earnings-call-transcript-analysis-report">Earnings Call Transcript Analysis Report</a></li>
    <li><a href="#financial-performance">Financial Performance</a>
      <ul>
        <li><a href="#key-financial-metrics-q3-fy25">Key Financial Metrics (Q3 FY25)</a></li>
        <li><a href="#key-financial-metrics-9m-fy25">Key Financial Metrics (9M FY25)</a></li>
        <li><a href="#guidance--forecasts">Guidance &amp; Forecasts</a></li>
        <li><a href="#areas-of-growth-or-decline">Areas of Growth or Decline</a></li>
      </ul>
    </li>
    <li><a href="#strategic-initiatives--business-updates">Strategic Initiatives &amp; Business Updates</a>
      <ul>
        <li><a href="#bsv-acquisition--integration">BSV Acquisition &amp; Integration</a></li>
        <li><a href="#corrective-measures">Corrective Measures</a></li>
        <li><a href="#product-portfolio--rd">Product Portfolio &amp; R&amp;D</a></li>
        <li><a href="#financial-strategy">Financial Strategy</a></li>
        <li><a href="#operational-changes">Operational Changes</a></li>
      </ul>
    </li>
    <li><a href="#market--competitive-landscape">Market &amp; Competitive Landscape</a>
      <ul>
        <li><a href="#market-share--positioning">Market Share &amp; Positioning</a></li>
        <li><a href="#industry-trends">Industry Trends</a></li>
        <li><a href="#competitive-actionsstatements">Competitive Actions/Statements</a></li>
        <li><a href="#market-challengesopportunities">Market Challenges/Opportunities</a></li>
      </ul>
    </li>
    <li><a href="#risk-factors--challenges">Risk Factors &amp; Challenges</a>
      <ul>
        <li><a href="#corrective-actions-impact">Corrective Actions Impact</a></li>
        <li><a href="#bsv-integration--restructuring">BSV Integration &amp; Restructuring</a></li>
        <li><a href="#regulatory-issues">Regulatory Issues</a></li>
        <li><a href="#financial-metrics-pressure">Financial Metrics Pressure</a></li>
        <li><a href="#operational-constraints">Operational Constraints</a></li>
      </ul>
    </li>
    <li><a href="#forward-looking-statements">Forward-Looking Statements</a>
      <ul>
        <li><a href="#overall-outlook">Overall Outlook</a></li>
        <li><a href="#corrective-measures-completion">Corrective Measures Completion</a></li>
        <li><a href="#bsv-business">BSV Business</a></li>
        <li><a href="#financial-targets">Financial Targets</a></li>
        <li><a href="#product-pipeline">Product Pipeline</a></li>
        <li><a href="#future-growth">Future Growth</a></li>
      </ul>
    </li>
  </ul>
</nav>
  </aside>
  

  

  <div class="single-content">
    <h2 class="heading" id="earnings-call-transcript-analysis-report">
  Earnings Call Transcript Analysis Report
  <a class="anchor" href="#earnings-call-transcript-analysis-report">#</a>
</h2>
<h2 class="heading" id="financial-performance">
  Financial Performance
  <a class="anchor" href="#financial-performance">#</a>
</h2>
<h3 class="heading" id="key-financial-metrics-q3-fy25">
  Key Financial Metrics (Q3 FY25)
  <a class="anchor" href="#key-financial-metrics-q3-fy25">#</a>
</h3>
<ul>
<li><strong>Revenue:</strong> INR 3,230 crores, up 24% YoY.
<ul>
<li>Organic growth: 11.2% YoY.</li>
<li>Domestic organic growth: 8.4% YoY.</li>
<li>Export organic growth: 43% YoY.</li>
</ul>
</li>
<li><strong>Adjusted EBITDA Margin:</strong> 27.7%.
<ul>
<li>Reported EBITDA: INR 833 crores, up 36.4% YoY, margin of 25.8%.</li>
</ul>
</li>
<li><strong>Gross Margins:</strong> Increased to 71% YoY from 68.3% in Q3 FY24.</li>
<li><strong>PAT:</strong> Decreased by 16.4% to INR 385 crores.</li>
<li><strong>Diluted EPS:</strong> INR 9.4 per share.</li>
<li><strong>Cash EPS:</strong> INR 14.2 per share.</li>
<li><strong>R&amp;D Expenses:</strong> INR 71 crores (2.2% of sales).</li>
<li><strong>Depreciation and Amortization:</strong> INR 192 crores (includes INR 84 crores amortization from BSV assets).</li>
</ul>
<h3 class="heading" id="key-financial-metrics-9m-fy25">
  Key Financial Metrics (9M FY25)
  <a class="anchor" href="#key-financial-metrics-9m-fy25">#</a>
</h3>
<ul>
<li><strong>Revenue:</strong> Increased by 17% YoY.</li>
<li><strong>Adjusted EBITDA Margin:</strong> 26.9%.
<ul>
<li>Reported EBITDA margin: 25.8%.</li>
</ul>
</li>
<li><strong>Organic Growth:</strong> 12.3% YoY.
<ul>
<li>Domestic organic growth: 9.3% YoY.</li>
<li>Export organic growth: 53% YoY.</li>
</ul>
</li>
<li><strong>Consolidated Effective Tax Rate:</strong> 21.2%.</li>
<li><strong>Cash Flow from Operations:</strong> INR 1,599 crores (down 2.3% YoY).</li>
<li><strong>Cash Flow to EBITDA Ratio:</strong> 67.4%.</li>
<li><strong>Capex Spends:</strong> INR 344 crores (3.7% of total revenue).</li>
</ul>
<h3 class="heading" id="guidance--forecasts">
  Guidance &amp; Forecasts
  <a class="anchor" href="#guidance--forecasts">#</a>
</h3>
<ul>
<li><strong>R&amp;D Expenses:</strong> Stated guidance of 2% to 2.5% of sales.</li>
<li><strong>Effective Tax Rate:</strong> Guidance of 21% to 22%.</li>
<li><strong>Capex:</strong> Guidance of 4% to 5% of revenue.</li>
<li><strong>Net Debt to Adjusted EBITDA:</strong> Endeavor to achieve 2x by end of FY25.</li>
<li><strong>Interest Cost (Next Quarter):</strong> Expected to be in the range of INR 180-odd crores.</li>
</ul>
<h3 class="heading" id="areas-of-growth-or-decline">
  Areas of Growth or Decline
  <a class="anchor" href="#areas-of-growth-or-decline">#</a>
</h3>
<ul>
<li><strong>Growth:</strong> Overall revenue (driven by both organic and BSV acquisition), export business (organic growth of 43% in Q3, 53% in 9M), OTC business (30% YoY in Q3, 15% YoY in 9M), Chronic segment share (increased by 200 bps YoY to 37.6% ex-BSV).</li>
<li><strong>Decline/Slowdown:</strong> PAT (due to higher finance and amortization costs), organic domestic formulation growth (around 6.5-7% in Q3, impacted by acute segment softness and corrective measures).</li>
<li><strong>Working Capital:</strong> Net operating working capital days increased to 52 days from 45 days in the preceding quarter.</li>
</ul>
<h2 class="heading" id="strategic-initiatives--business-updates">
  Strategic Initiatives &amp; Business Updates
  <a class="anchor" href="#strategic-initiatives--business-updates">#</a>
</h2>
<h3 class="heading" id="bsv-acquisition--integration">
  BSV Acquisition &amp; Integration
  <a class="anchor" href="#bsv-acquisition--integration">#</a>
</h3>
<ul>
<li>Acquisition completed, BSV financials consolidated from October 23rd, 2024 (69 days in Q3).</li>
<li>Integration is &ldquo;on track.&rdquo;</li>
<li>Significant restructuring in the Rx business (TTK business of BSV), shifting to Mankind, field force optimization.</li>
<li>Synergy benefits expected: INR 50-100 crores over 12-24 months.</li>
</ul>
<h3 class="heading" id="corrective-measures">
  Corrective Measures
  <a class="anchor" href="#corrective-measures">#</a>
</h3>
<ul>
<li><strong>Delhi Pharma Divisions:</strong> Undertaken to enhance field force productivity and efficiency. Nearing completion (80-90% done).
<ul>
<li>Measures include addressing inefficiencies in primary/discounted sales, doctor coverage strategy, leadership changes.</li>
</ul>
</li>
<li><strong>OTC Division:</strong> Corrective measures completed, leading to robust growth.</li>
</ul>
<h3 class="heading" id="product-portfolio--rd">
  Product Portfolio &amp; R&amp;D
  <a class="anchor" href="#product-portfolio--rd">#</a>
</h3>
<ul>
<li>Expansion of DMF grade products: Over 215 (vs 150 in FY24), &gt;90% in chronic segment.</li>
<li>Partnership with Innovent Biologics: In-licensing of Sintilimab (PD-1 immunotherapy for cancer treatment).</li>
</ul>
<h3 class="heading" id="financial-strategy">
  Financial Strategy
  <a class="anchor" href="#financial-strategy">#</a>
</h3>
<ul>
<li>Raised INR 10,000 crores (NCDs &amp; CPs) for BSV acquisition.</li>
<li>Raised INR 3,000 crores in equity, used to repay CPs.</li>
</ul>
<h3 class="heading" id="operational-changes">
  Operational Changes
  <a class="anchor" href="#operational-changes">#</a>
</h3>
<ul>
<li>OTC business carved out into a wholly-owned subsidiary.</li>
<li>Field force strength (Mankind): Increased from 16,043 (Mar 2024) to 16,570 (Dec 2024). Not cutting down, but replacing and optimizing.</li>
</ul>
<h2 class="heading" id="market--competitive-landscape">
  Market &amp; Competitive Landscape
  <a class="anchor" href="#market--competitive-landscape">#</a>
</h2>
<h3 class="heading" id="market-share--positioning">
  Market Share &amp; Positioning
  <a class="anchor" href="#market-share--positioning">#</a>
</h3>
<ul>
<li>IPM market share (value): Increased by 40 bps to 4.8% (Dec &lsquo;24) from 4.4% (Mar &lsquo;24), &ldquo;primarily driven by acquisition of BSV.&rdquo;</li>
<li>CVM Cardio Rank: Improved from 4th to 3rd in IPM.</li>
<li>Aiming for leadership.</li>
</ul>
<h3 class="heading" id="industry-trends">
  Industry Trends
  <a class="anchor" href="#industry-trends">#</a>
</h3>
<ul>
<li><strong>Chronic Segment Growth:</strong> Continued outperformance in key chronic therapies. Mankind&rsquo;s chronic share (ex-BSV) increased to 37.6% in Q3 FY25 from 35.6% in Q3 FY24.</li>
<li><strong>Cancer Incidence:</strong> Rising cancer cases in India, creating demand for innovative therapies like Sintilimab.</li>
</ul>
<h3 class="heading" id="competitive-actionsstatements">
  Competitive Actions/Statements
  <a class="anchor" href="#competitive-actionsstatements">#</a>
</h3>
<ul>
<li>Focus on &ldquo;high entry barrier portfolios&rdquo; and &ldquo;specialty R&amp;D tech platforms&rdquo; through acquisitions like BSV.</li>
<li>Corrective measures aimed at improving competitiveness and field force productivity against market.</li>
</ul>
<h3 class="heading" id="market-challengesopportunities">
  Market Challenges/Opportunities
  <a class="anchor" href="#market-challengesopportunities">#</a>
</h3>
<ul>
<li><strong>Challenge:</strong> Softer acute market for Mankind due to corrective measures and some regulatory impacts.</li>
<li><strong>Opportunity:</strong> Expanding into specialty/super-specialty segments (BSV), growing chronic market, robust OTC market potential.</li>
</ul>
<h2 class="heading" id="risk-factors--challenges">
  Risk Factors &amp; Challenges
  <a class="anchor" href="#risk-factors--challenges">#</a>
</h2>
<h3 class="heading" id="corrective-actions-impact">
  Corrective Actions Impact
  <a class="anchor" href="#corrective-actions-impact">#</a>
</h3>
<ul>
<li>Temporary slowdown in growth, especially in the acute segment of the domestic pharma business.</li>
</ul>
<h3 class="heading" id="bsv-integration--restructuring">
  BSV Integration &amp; Restructuring
  <a class="anchor" href="#bsv-integration--restructuring">#</a>
</h3>
<ul>
<li>Ongoing integration process for BSV.</li>
<li>Restructuring of BSV&rsquo;s Rx business leading to soft performance in that segment.</li>
</ul>
<h3 class="heading" id="regulatory-issues">
  Regulatory Issues
  <a class="anchor" href="#regulatory-issues">#</a>
</h3>
<ul>
<li>Impact on acute segment growth from regulatory tailwinds concerning emergency contraceptive pills, an FDC anti-infective, and a codeine preparation.</li>
<li>DPCO matter affecting value growth in a gynaecology product.</li>
</ul>
<h3 class="heading" id="financial-metrics-pressure">
  Financial Metrics Pressure
  <a class="anchor" href="#financial-metrics-pressure">#</a>
</h3>
<ul>
<li>Higher finance costs and amortization from BSV acquisition impacting PAT.</li>
<li>Increased working capital days.</li>
</ul>
<h3 class="heading" id="operational-constraints">
  Operational Constraints
  <a class="anchor" href="#operational-constraints">#</a>
</h3>
<ul>
<li>New field force members (due to replacements during corrective actions) need time to build rapport and productivity.</li>
</ul>
<h2 class="heading" id="forward-looking-statements">
  Forward-Looking Statements
  <a class="anchor" href="#forward-looking-statements">#</a>
</h2>
<h3 class="heading" id="overall-outlook">
  Overall Outlook
  <a class="anchor" href="#overall-outlook">#</a>
</h3>
<ul>
<li>Confident in delivering sustainable long-term growth, supported by corrective actions and four growth engines.</li>
</ul>
<h3 class="heading" id="corrective-measures-completion">
  Corrective Measures Completion
  <a class="anchor" href="#corrective-measures-completion">#</a>
</h3>
<ul>
<li>Remaining 10-20% of corrective actions in Delhi pharma divisions to be completed in Q4 FY25.</li>
</ul>
<h3 class="heading" id="bsv-business">
  BSV Business
  <a class="anchor" href="#bsv-business">#</a>
</h3>
<ul>
<li>Priority is successful integration for long-term sustainable growth.</li>
<li>Expected to grow 15%+ with higher export growth in the medium term.</li>
<li>Margin improvement targeted: Starting at company average (26-28%), aiming for ~30% in 2-3 years, and &ldquo;for sure in the next 5 years.&rdquo;</li>
<li>Rx business restructuring (TTK) to see improvements from Q4 onwards.</li>
</ul>
<h3 class="heading" id="financial-targets">
  Financial Targets
  <a class="anchor" href="#financial-targets">#</a>
</h3>
<ul>
<li>Net debt to adjusted EBITDA: Target of 2x by end of FY25.</li>
<li>Interest cost next quarter: Around INR 180 crores.</li>
</ul>
<h3 class="heading" id="product-pipeline">
  Product Pipeline
  <a class="anchor" href="#product-pipeline">#</a>
</h3>
<ul>
<li>Planning to introduce a replacement (single molecule) for the anti-infective FDC affected by regulatory issues within a month.</li>
</ul>
<h3 class="heading" id="future-growth">
  Future Growth
  <a class="anchor" href="#future-growth">#</a>
</h3>
<ul>
<li>Expects growth to improve post-completion of corrective measures.</li>
<li>Chronic PCPM expected to grow faster and eventually align with company average.</li>
</ul>



<div class="button-container">    
    <a href="https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=09cab4ef-bf88-40b1-be1e-cabdff929690.pdf" target="_blank" class="report-button">
      <i class="fas fa-file-pdf"></i> Download Transcript
    </a>
</div>
    



    
  </div>

  


  

  
  

<div class="single-pagination">
    <hr />

    <div class="flex">

        <div class="single-pagination-prev">
            
            <div class="single-pagination-container-prev">
                <div class="single-pagination-text">←</div>
                <div class="single-pagination-text">
                    <a href="/posts/zensar-technologies-ltd---jan-2025-earnings-call-transcript-analysis/">
                        Zensar Technologies Ltd - Jan 2025 Earnings Call Transcript Analysis
                    </a>
                </div>
            </div>
            
        </div>

        <div class="single-pagination-next">
            
            <div class="single-pagination-container-next">
                <div class="single-pagination-text">
                    <a href="/posts/capri-global-capital-ltd---jan-2025-earnings-call-transcript-analysis/">
                        Capri Global Capital Ltd - Jan 2025 Earnings Call Transcript Analysis
                    </a>
                </div>
                <div class="single-pagination-text">→</div>
            </div>
            
        </div>

    </div>

    <hr />
</div>



  <div id="disqus_thread"></div>
<script>
    

    

    (function() { 
    var d = document, s = d.createElement('script');
    s.src = 'https://muthuai.disqus.com/embed.js';
    s.setAttribute('data-timestamp', +new Date());
    (d.head || d.body).appendChild(s);
    })();
</script>
<noscript>Please enable JavaScript to view the <a href="https://disqus.com/?ref_noscript">comments powered by Disqus.</a></noscript>
  

  

  
  <div class="back-to-top">
    <a href="#top">
      back to top
    </a>
  </div>
  

</div>


    </main>
  </div>

  <footer>
    

    
    
    
    <p>Made with ♥ in India</p>
    


  </footer>

  

</body>

<script>

  function isAuto() {
    return document.body.classList.contains("auto");
  }

  function setTheme() {
    if (!isAuto()) {
      return
    }

    document.body.classList.remove("auto");
    let cls = "light";
    if (window.matchMedia && window.matchMedia('(prefers-color-scheme: dark)').matches) {
      cls = "dark";
    }

    document.body.classList.add(cls);
  }

  function invertBody() {
    document.body.classList.toggle("dark");
    document.body.classList.toggle("light");
  }

  if (isAuto()) {
    window.matchMedia('(prefers-color-scheme: dark)').addListener(invertBody);
  }

  setTheme();

</script>
<script>
    window.addEventListener('DOMContentLoaded', (event) => {
        new PagefindUI({ element: "#search", showSubResults: false, showImages: false });
    });
</script>
<script defer src="/js/copy-code.js"></script>
</html>